A Phase 2 interventional study of Guselkumab and Golimumab in Arthritis, Psoriatic, sponsored by Janssen Research & Development, LLC. Completed at 82 sites in 10 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by Janssen Research & Development, LLC · Phase 2, Interventional, and Treatment
The purpose of this study is to evaluate the efficacy of guselkumab plus golimumab combination treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) to prior anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapies by assessing clinical response compared with guselkumab monotherapy.
PsA is a chronic inflammatory multi-faceted disease that impacts the peripheral and axial joints, soft tissues, and skin. Guselkumab is a fully human monoclonal antibody (mAb) directed against the p19 subunit of interleukin (IL)-23, blocks the binding of extracellular IL-23 to the cell surface IL-23 receptor, inhibiting IL-23 specific intracellular signaling, subsequent activation, and cytokine production. Golimumab is a fully human anti-TNF-alpha mAb that binds to TNF-alpha with high affinity, prevents binding to its receptors, thereby inhibiting the biological activity of TNF-alpha and resulting in limited production or activity of inflammatory cytokines, thereby providing therapeutic benefit in various chronic inflammatory disorders, including PsA. This study will consist of a Screening Phase (up to 6 weeks), Double-blind Phase from Weeks 0 to 24 which includes the active treatment phase and the primary efficacy visit (Week 24), and Safety Follow-up Phase from Week 24 to Week 36. Key safety assessments will include adverse events (AEs), clinical laboratory safety tests (hematology and chemistry), vital signs, monitoring for injection-site and hypersensitivity reactions, and early detection of active tuberculosis (TB). The total duration of the study is up to 42 weeks.
579 studies on the registry are indexed under Arthritis, Psoriatic; 132 are open to participants now.
This study's enrollment of 91 is below the median of 135 across 322 interventional studies indexed under Arthritis, Psoriatic.
Browse Arthritis, Psoriatic studies →Janssen Research & Development, LLC is the lead sponsor of 912 studies on the registry; 76 are open to participants now.
Of its 278 completed or terminated interventional studies of FDA-regulated products, 131 (47%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants will receive subcutaneous (SC) guselkumab and golimumab.
Drug: Guselkumab · Drug: Golimumab
Participants will receive SC guselkumab and placebo.
Drug: Guselkumab · Drug: Placebo
Guselkumab will be administered as a SC injection.
Also known as: TREMFYA, CNTO1959
Golimumab will be administered as a SC injection.
Also known as: SIMPONI, CNTO148
Placebo will be administered as a SC injection.
Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Week 24
MDA was a measure that defines a satisfactory state of disease activity that includes 5 domains of psoriatic arthritis (PsA) (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity on arthritis and psoriasis, physical function and enthesitis). Participants were classified as achieving MDA if they fulfilled 5 of the following 7 criteria at that visit: Tender joint count (68 joints) \<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index (PASI) \<=1, Patient's Assessment of Pain \<=15 on a 100-unit visual analog scale (VAS), Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, Disability Index of the Health Assessment Questionnaire (HAQ-DI) score \<=0.5, and Tender entheseal points \<= 1 (Leeds Enthesitis Index \[LEI\] score \<= 1).
Time frame: Week 24
Percentage of Participants Who Achieved American College of Rheumatology (ACR) 50 at Week 24
ACR 50 response was defined as greater than or equal to (\>=) 50% improvement from baseline in both swollen joint (66 joints) and tender joint counts (68 joints) and \>=50% improvement from baseline in \>=3 of 5 assessments: Physician global assessment of disease activity (0 to 100 millimeters \[mm\] VAS \[0=no arthritis activity and 100=extremely active arthritis\]), Patient global assessment of disease activity (arthritis) (100 mm VAS \[0 = no limitation of normal activities; 100 = very poor\]), Patient's global assessment of pain (100 mm VAS \[0 = no pain; 100 = most severe pain\]), patient's assessment of physical function measured by HAQ-DI (20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and high-sensitivity C-reactive protein (hsCRP).
Time frame: Week 24
Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Week 16
MDA was a measure that defines a satisfactory state of disease activity that includes 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity on arthritis and psoriasis, physical function and enthesitis). Participants were classified as achieving MDA if they fulfilled 5 of the following 7 criteria at that visit: Tender joint count (68 joints) \<=1, Swollen joint count (66 joints) \<=1, PASI \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI score \<= 1).
Time frame: Week 16
Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 24 Among Participants With >= 3% Body Surface Area (BSA) Psoriatic Involvement and an Investigator Global Assessment (IGA) Score of >=2 (Mild) at Baseline
PASI 90 response was defined as at least a 90% reduction in PASI relative to baseline. PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: head and neck, trunk (including axillae and groin), upper extremities, and lower extremities (included buttocks). Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 to 100% involvement), and erythema, induration and scaling, each rated on a scale of 0 to 4, that was none to maximum severity. PASI produces a numeric score range from 0 (no psoriasis) to 72 (worst condition). Higher scores indicated more severe disease.
Time frame: Week 24
Percentage of Participants Who Achieved PASI 100 Response at Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
PASI 100 response was defined as 100% reduction in PASI relative to baseline. PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: head and neck, trunk (including axillae and groin), upper extremities, and lower extremities (included buttocks). Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 to 100% involvement), and erythema, induration and scaling, each rated on a scale of 0 to 4, that was none to maximum severity. PASI produces a numeric score range from 0 (no psoriasis) to 72 (worst condition). Higher scores indicated more severe disease.
Time frame: Week 24
Percentage of Participants With an IGA-psoriasis Response at Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
IGA psoriasis response was defined as an IGA psoriasis score of 0 (cleared) or 1 (minimal) and \>=2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions were graded for induration, erythema, and scaling each using a 5 point scale: clear (0), minimal (1), mild (2), moderate (3), and severe (4). The IGA score of psoriasis was based upon the average of induration, erythema, and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Time frame: Week 24
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 24
Change from baseline in HAQ-DI score was a measure of the change in the physical function. It consists of a 20-questions instrument that assesses the degree of difficulty a person had in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0 = no difficulty to 3= inability to perform a task. Scores on each task were summed and averaged to provide an overall HAQ-DI total score ranging from 0 (least difficulty) to 3 (extreme difficulty). Lower scores indicated better functioning. Negative change from baseline indicated improvement of physical function.
Time frame: Baseline (Week 0), Week 24
Percentage of Participants Who Had Resolution of Enthesitis at Week 24 Among the Participants With Enthesitis at Baseline
Enthesitis assessed using the Leeds Enthesitis Index (LEI), a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of tenderness by applying local pressure to the following enthesis sites: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. Each site was scored as 1 if tenderness was present or 0 if tenderness was absent. The enthesitis index score was a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Higher score indicated more sites with tenderness. A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI \>0.
Time frame: Week 24
Percentage of Participants Who Achieved Resolution of Dactylitis Response at Week 24 Among the Participants With Dactylitis at Baseline
Dactylitis was characterized by swelling in both hands and feet. The severity of dactylitis was scored on a scale from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results for each digit summed to produce final dactylitis score which was from 0 to 60. Higher score indicates more severe dactylitis. Dactylitis count was derived based on dactylitis score, each score was recorded to 0 or 1 from 0 to 3, where any score \>0 was recorded as 1. For resolution of dactylitis, it was defined as participants who had a dactylitis score greater than 0 at baseline and a score of 0 at the analysis visit.
Time frame: Week 24
Change From Baseline in Short Form Health Survey (SF-36) Physical Component Score (PCS) at Week 24
SF-36 was a multi-domain instrument with 36 items to evaluate health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health). The scores for the 8 domains were combined into two summary scores: the physical component summary (PCS) score and the mental component summary (MCS) score. Domains 1 to 4 primarily contribute to the PCS score of the SF-36. Domains 5-8 primarily contributes to the MCS score of the SF-36. Each of the 8 domain scores and the component summary score ranged from 0=worst to 100=best. Higher scores represent better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline (Week 0), Week 24
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were any AE occurred at or after the initial administration of study intervention through the day of last dose plus 16 weeks.
Time frame: From Week 0 up to Week 36
Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
SAE was defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, led to a congenital anomaly/birth defect in the offspring of a participant, or was an important medical event. TESAEs were any SAE occurred at or after the initial administration of study intervention through the day of last dose plus 16 weeks.
Time frame: From Week 0 up to Week 36
Percentage of Participants With Reasonably Related Adverse Events (AEs)
Percentage of participants with reasonably related AEs was reported. An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. AE reasonably related to guselkumab or golimumab were defined as AEs classified by the investigator as related to study agent.
Time frame: From Week 0 up to Week 36
Percentage of Participants With AEs Leading to Discontinuation of Study Intervention
Percentage of participants with AEs leading to discontinuation of study intervention was reported. AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.
Time frame: From Week 0 to Week 20
Percentage of Participants With Infections
Percentage of participants with infections was reported. Investigators evaluate participants for any signs or symptoms of infection. An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product.
Time frame: From Week 0 up to Week 36
Percentage of Participants With Injection-site Reactions
Percentage of participants with injection-site reaction was reported. A study intervention injection-site reaction was any adverse reaction at a subcutaneous study intervention injection-site. The injection sites were evaluated for reactions, and any injection-site reaction was recorded as an AE. Injection site reactions were significant bruising, erythema, hemorrhage, irritation, pain, and pruritus.
Time frame: From Week 0 up to Week 36
Group 1: Guselkumab Plus Golimumab - Serum Concentration of Golimumab
Serum concentration of golimumab was reported.
Time frame: Weeks 0, 4, 8, 12, 16, 20, 24, and 36
Serum Concentration of Guselkumab
Serum concentration of guselkumab was reported.
Time frame: Weeks 0, 4, 8, 12, 16, 20, 24, and 36
Percentage of Participants With Anti-Guselkumab Antibodies
Percentage of participants with anti-guselkumab antibodies was reported.
Time frame: From Week 0 up to Week 36
Percentage of Participants With Anti-Golimumab Antibodies
Percentage of participants with anti-golimumab antibodies were reported.
Time frame: From Week 0 up to Week 36
| Milestone | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo |
|---|---|---|
| Started | 59 | 32 |
| Completed | 48 | 28 |
| Not completed | 11 | 4 |
| Withdrew: Withdrawal by subject | 3 | 3 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Other | 5 | 1 |
MDA was a measure that defines a satisfactory state of disease activity that includes 5 domains of psoriatic arthritis (PsA) (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity on arthritis and psoriasis, physical function and enthesitis). Participants were classified as achieving MDA if they fulfilled 5 of the following 7 criteria at that visit: Tender joint count (68 joints) \<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index (PASI) \<=1, Patient's Assessment of Pain \<=15 on a 100-unit visual analog scale (VAS), Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, Disability Index of the Health Assessment Questionnaire (HAQ-DI) score \<=0.5, and Tender entheseal points \<= 1 (Leeds Enthesitis Index \[LEI\] score \<= 1).
| Percentage of participants | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo |
|---|---|---|
| Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Week 24 | 28.8 | 21.9 |
ACR 50 response was defined as greater than or equal to (\>=) 50% improvement from baseline in both swollen joint (66 joints) and tender joint counts (68 joints) and \>=50% improvement from baseline in \>=3 of 5 assessments: Physician global assessment of disease activity (0 to 100 millimeters \[mm\] VAS \[0=no arthritis activity and 100=extremely active arthritis\]), Patient global assessment of disease activity (arthritis) (100 mm VAS \[0 = no limitation of normal activities; 100 = very poor\]), Patient's global assessment of pain (100 mm VAS \[0 = no pain; 100 = most severe pain\]), patient's assessment of physical function measured by HAQ-DI (20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and high-sensitivity C-reactive protein (hsCRP).
| Percentage of participants | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo |
|---|---|---|
| Percentage of Participants Who Achieved American College of Rheumatology (ACR) 50 at Week 24 | 44.1 | 21.9 |
MDA was a measure that defines a satisfactory state of disease activity that includes 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity on arthritis and psoriasis, physical function and enthesitis). Participants were classified as achieving MDA if they fulfilled 5 of the following 7 criteria at that visit: Tender joint count (68 joints) \<=1, Swollen joint count (66 joints) \<=1, PASI \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI score \<= 1).
| Percentage of participants | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo |
|---|---|---|
| Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Week 16 | 32.2 | 12.5 |
PASI 90 response was defined as at least a 90% reduction in PASI relative to baseline. PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: head and neck, trunk (including axillae and groin), upper extremities, and lower extremities (included buttocks). Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 to 100% involvement), and erythema, induration and scaling, each rated on a scale of 0 to 4, that was none to maximum severity. PASI produces a numeric score range from 0 (no psoriasis) to 72 (worst condition). Higher scores indicated more severe disease.
| Percentage of participants | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo |
|---|---|---|
| Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 24 Among Participants With >= 3% Body Surface Area (BSA) Psoriatic Involvement and an Investigator Global Assessment (IGA) Score of >=2 (Mild) at Baseline | 54.5 | 38.5 |
PASI 100 response was defined as 100% reduction in PASI relative to baseline. PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: head and neck, trunk (including axillae and groin), upper extremities, and lower extremities (included buttocks). Each of these areas was assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 to 100% involvement), and erythema, induration and scaling, each rated on a scale of 0 to 4, that was none to maximum severity. PASI produces a numeric score range from 0 (no psoriasis) to 72 (worst condition). Higher scores indicated more severe disease.
| Percentage of participants | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo |
|---|---|---|
| Percentage of Participants Who Achieved PASI 100 Response at Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline | 31.8 | 30.8 |
IGA psoriasis response was defined as an IGA psoriasis score of 0 (cleared) or 1 (minimal) and \>=2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions were graded for induration, erythema, and scaling each using a 5 point scale: clear (0), minimal (1), mild (2), moderate (3), and severe (4). The IGA score of psoriasis was based upon the average of induration, erythema, and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
| Percentage of participants | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo |
|---|---|---|
| Percentage of Participants With an IGA-psoriasis Response at Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline | 54.5 | 61.5 |
Change from baseline in HAQ-DI score was a measure of the change in the physical function. It consists of a 20-questions instrument that assesses the degree of difficulty a person had in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0 = no difficulty to 3= inability to perform a task. Scores on each task were summed and averaged to provide an overall HAQ-DI total score ranging from 0 (least difficulty) to 3 (extreme difficulty). Lower scores indicated better functioning. Negative change from baseline indicated improvement of physical function.
| Units on a scale | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo |
|---|---|---|
| Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 24 | -0.39 (-0.51 to -0.28) | -0.26 (-0.42 to -0.10) |
Enthesitis assessed using the Leeds Enthesitis Index (LEI), a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of tenderness by applying local pressure to the following enthesis sites: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. Each site was scored as 1 if tenderness was present or 0 if tenderness was absent. The enthesitis index score was a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Higher score indicated more sites with tenderness. A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI \>0.
| Percentage of participants | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo |
|---|---|---|
| Percentage of Participants Who Had Resolution of Enthesitis at Week 24 Among the Participants With Enthesitis at Baseline | 48.6 | 52.4 |
Dactylitis was characterized by swelling in both hands and feet. The severity of dactylitis was scored on a scale from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results for each digit summed to produce final dactylitis score which was from 0 to 60. Higher score indicates more severe dactylitis. Dactylitis count was derived based on dactylitis score, each score was recorded to 0 or 1 from 0 to 3, where any score \>0 was recorded as 1. For resolution of dactylitis, it was defined as participants who had a dactylitis score greater than 0 at baseline and a score of 0 at the analysis visit.
| Percentage of participants | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo |
|---|---|---|
| Percentage of Participants Who Achieved Resolution of Dactylitis Response at Week 24 Among the Participants With Dactylitis at Baseline | 61.5 | 87.5 |
SF-36 was a multi-domain instrument with 36 items to evaluate health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health). The scores for the 8 domains were combined into two summary scores: the physical component summary (PCS) score and the mental component summary (MCS) score. Domains 1 to 4 primarily contribute to the PCS score of the SF-36. Domains 5-8 primarily contributes to the MCS score of the SF-36. Each of the 8 domain scores and the component summary score ranged from 0=worst to 100=best. Higher scores represent better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| Units on a scale | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo |
|---|---|---|
| Change From Baseline in Short Form Health Survey (SF-36) Physical Component Score (PCS) at Week 24 | 8.84 (6.88 to 10.80) | 3.59 (0.92 to 6.26) |
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were any AE occurred at or after the initial administration of study intervention through the day of last dose plus 16 weeks.
| Percentage of participants | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo |
|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | 71.2 | 56.3 |
SAE was defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, led to a congenital anomaly/birth defect in the offspring of a participant, or was an important medical event. TESAEs were any SAE occurred at or after the initial administration of study intervention through the day of last dose plus 16 weeks.
| Percentage of participants | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo |
|---|---|---|
| Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs) | 6.8 | 0 |
Percentage of participants with reasonably related AEs was reported. An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. AE reasonably related to guselkumab or golimumab were defined as AEs classified by the investigator as related to study agent.
| Percentage of participants | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo |
|---|---|---|
| Percentage of Participants With Reasonably Related Adverse Events (AEs) | 35.6 | 21.9 |
Percentage of participants with AEs leading to discontinuation of study intervention was reported. AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.
| Percentage of participants | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo |
|---|---|---|
| Percentage of Participants With AEs Leading to Discontinuation of Study Intervention | 3.4 | 0 |
Percentage of participants with infections was reported. Investigators evaluate participants for any signs or symptoms of infection. An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product.
| Percentage of participants | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo |
|---|---|---|
| Percentage of Participants With Infections | 32.2 | 40.6 |
Percentage of participants with injection-site reaction was reported. A study intervention injection-site reaction was any adverse reaction at a subcutaneous study intervention injection-site. The injection sites were evaluated for reactions, and any injection-site reaction was recorded as an AE. Injection site reactions were significant bruising, erythema, hemorrhage, irritation, pain, and pruritus.
| Percentage of participants | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo |
|---|---|---|
| Percentage of Participants With Injection-site Reactions | 10.2 | 3.1 |
Serum concentration of golimumab was reported.
| Micrograms per milliliter | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w |
|---|---|
| Week 0 | 0.02 ± 0.136 |
| Week 4 | 0.78 ± 1.749 |
| Week 8 | 0.68 ± 0.670 |
| Week 12 | 0.97 ± 2.316 |
| Week 16 | 0.73 ± 0.646 |
| Week 20 | 0.57 ± 0.399 |
| Week 24 | 0.56 ± 0.424 |
| Week 36 | 0.06 ± 0.250 |
Serum concentration of guselkumab was reported.
| Micrograms per milliliter | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo |
|---|---|---|
| Week 0 | 0.05 ± 0.288 | 0.0 ± 0.000 |
| Week 4 | 2.34 ± 1.338 | 2.41 ± 1.527 |
| Week 8 | 3.36 ± 2.266 | 3.56 ± 2.370 |
| Week 12 | 3.62 ± 2.342 | 4.04 ± 2.785 |
| Week 16 | 3.95 ± 2.188 | 4.19 ± 2.963 |
| Week 20 | 3.85 ± 2.214 | 4.13 ± 2.954 |
| Week 24 | 3.96 ± 2.297 | 3.64 ± 2.850 |
| Week 36 | 0.95 ± 1.587 | 1.00 ± 1.764 |
Percentage of participants with anti-guselkumab antibodies was reported.
| Percentage of participants | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo |
|---|---|---|
| Percentage of Participants With Anti-Guselkumab Antibodies | 11.9 | 15.6 |
Percentage of participants with anti-golimumab antibodies were reported.
| Percentage of participants | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w |
|---|---|
| Percentage of Participants With Anti-Golimumab Antibodies | 67.8 |
Collected over All-cause mortality: From screening (Week -6) up to Week 36; SAE and other AEs: From Week 0 up to Week 36. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | 0/59 (0%) | 4/59 (6.8%) | 25/59 (42.4%) |
| Group 2: Guselkumab 100 mg q4w Plus Placebo | 0/32 (0%) | 0/32 (0%) | 10/32 (31.3%) |
| Event | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo |
|---|---|---|
| Covid-19Infections and infestations | 1/59 | 0/32 |
| Pneumonia MycoplasmalInfections and infestations | 1/59 | 0/32 |
| Neuroendocrine TumourNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/59 | 0/32 |
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 1/59 | 0/32 |
| Event | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 7/59 | 0/32 |
| HeadacheNervous system disorders | 7/59 | 1/32 |
| NasopharyngitisInfections and infestations | 5/59 | 3/32 |
| Covid-19Infections and infestations | 5/59 | 2/32 |
| Psoriatic ArthropathyMusculoskeletal and connective tissue disorders | 5/59 | 0/32 |
| NauseaGastrointestinal disorders | 4/59 | 0/32 |
| Back PainMusculoskeletal and connective tissue disorders | 4/59 | 0/32 |
| InfluenzaInfections and infestations | 2/59 | 2/32 |
| Oral CandidiasisInfections and infestations | 0/59 | 2/32 |
| Upper Respiratory Tract InfectionInfections and infestations | 3/59 | 2/32 |
| Age, Categorical(Participants) | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 57 | 31 | 88 |
| >=65 years | 2 | 1 | 3 |
| Age, Continuous(Years) | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo | Total |
|---|---|---|---|
| Mean | 50.2 ± 10.53 | 47.7 ± 10.34 | 49.4 ± 10.47 |
| Sex: Female, Male(Participants) | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo | Total |
|---|---|---|---|
| Female | 36 | 20 | 56 |
| Male | 23 | 12 | 35 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 18 | 5 | 23 |
| Not Hispanic or Latino | 38 | 26 | 64 |
| Unknown or Not Reported | 3 | 1 | 4 |
| Race (NIH/OMB)(Participants) | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 57 | 32 | 89 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Region of Enrollment(Participants) | Group 1: Guselkumab 100 mg q4w Plus Golimumab 50 mg q4w | Group 2: Guselkumab 100 mg q4w Plus Placebo | Total |
|---|---|---|---|
| Denmark | 5 | 7 | 12 |
| France | 1 | 0 | 1 |
| Hungary | 5 | 1 | 6 |
| Italy | 6 | 4 | 10 |
| Poland | 1 | 1 | 2 |
| Russian Federation | 2 | 2 | 4 |
| Spain | 16 | 6 | 22 |
| Ukraine | 3 | 0 | 3 |
| United States | 20 | 11 | 31 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Janssen Research & Development, LLC